Welcome to the e-CCO Library!

P383: Ustekinumab as an opportunity for refractory Ulcerative Colitis patients.
Year: 2022
Source: ECCO'22
Authors: Iborra, M.(1);Soutullo, C.(1);Gimeno, M.(1);Bastida, G.(1);Aguas, M.(1);Cerrillo, E.(1);Sáez-González, E.(1);Garrido, A.(1);Mínguez, A.(1);Bordetas, J.(1);Nos, P.(1);
Created: Friday, 11 February 2022, 3:52 PM
P384 Lower infliximab trough levels are associated with higher bowel wall thickness in Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Frias Gomes1, B. Morão1, C. Neto Nascimento1, C. Gouveia1, C. Palmela1, J. Strecht2, J. Torres1

Created: Thursday, 30 January 2020, 10:12 AM
P384: A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn's Disease: first results of a prospective cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Van De Meeberg, M.(1)*;Fidder, H.(2);Sundaresan, J.(3);Struys, E.(3);Oldenburg, B.(2);Mares, W.(4);Mahmmod, N.(5);van Asseldonk, D.(6);Lutgens, M.(7);Kuyvenhoven, J.(8);Rietdijk, S.(9);Nissen, L.(10);Koehestanie, P.(11);de Jonge, R.(3);Bulatović Ćalasan, M.(12);Bouma, G.(13);
Created: Friday, 14 July 2023, 11:05 AM
P384: Gari-leo prospective study on anti-TNF therapy in ulcerative colitis relapse patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Kato*, K. Kani, A. Ishibashi, M. Oka, S. Nagoshi, K. Yakabi

Created: Thursday, 21 February 2019, 9:14 AM
P384: High incidence of hyperglycaemia in steroid treated hospitalised inflammatory bowel disease (IBD) patients and its risk factors identified by machine learning methods
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. McDonnell*1, R. Harris1, T. Mills1, L. Downey1, S. Dharmasiri1, R. Felwick1, F. Borca2, H. Phan2, F. Cummings1,3, M. Gwiggner1

Created: Friday, 22 February 2019, 9:41 AM
P384: Long-term outcome and endoscopic healing rates following long modified side-to-side strictureplasties
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Van Stappen J.*1, De Buck van Overstraeten A.2, Ferrante M.1, Vanbeckevoort D.3, Van Assche G.1, D'Hoore A.2, Vermeire S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P384: Postoperative Endoscopic Recurrence In Patients With Crohn’s Disease After “Curative” Ileocecal Resection on Prophylaxis Treatment With Either Anti-TNFs, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
Year: 2022
Source: ECCO'22
Authors: Yanai, H.(1,2);Amir Barak , H.(1,2);Kagramanova, A.(3);Knyazev , O.(3);Sabino, J.(4);Haenen, S.(4);Mantzaris , G.J.(5);Mountaki, K.(5);Pugliese, D.(6);Armuzzi, A.(6,7);Furfaro, F.(8);Fiorino, G.(8);Drobne, D.(9,10);Kurent, T.(10);Yassin, S.(2,11);Maharshak, N.(2,11);Castiglione, F.(12);Nardone, O.M.(12);de Sire, R.(12);Farkas, K.(13);Molnar, T.(13);Krznaric, Z.(14);Brinar, M.(14);Chashkova, E.(15);Margolin, M.L.(2,16);Kopylov, U.(2,16);Bezzio, C.(17);Bar-Gil Shitrit, A.(18);Lukas , M.(19,20);Chaparro, M.(21);Truyens, M.(22,23);Nancey, S.(24);Revés, J.(25);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Dotan, I.(1,2);Aharoni Golan, M.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P384: The usefulness of salazosulfapyridine for 
patients with ulcerative colitis refractory to mesalazine
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Yoshino*, S. Yazumi

Created: Friday, 22 February 2019, 9:49 AM
P384: Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick
Year: 2021
Source: ECCO'21 Virtual
Authors: Ametzazurra, A.(1);Pascual, J.(1);Del Rio, L.(1);Maguregui, A.(1);Nagore, D.(1);Ruiz-Argüello, M.B.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Verstockt1, S. Verstockt2, D. Alsaoud2, J. Sabino1, M. Ferrante1, S. Vermeire1

Created: Thursday, 30 January 2020, 10:12 AM
P385: Assessment of long-term outcomes of patients with ulcerative colitis and mucosal healing under different therapies: Is all mucosal healing the same?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Raimundo Fernandes S.*1, Correia L.1, Baldaia C.2, Moura Santos P.2, Rita Gonçalves A.2, Valente A.2, Velosa J.1

Created: Wednesday, 20 February 2019, 10:36 AM
P385: Colectomy-free survival and factors associated with it in children with ulcerative colitis managed in a tertiary IBD centre in the UK
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.-Y. Ong*, W. Haller, R. Muhammed

Created: Thursday, 21 February 2019, 9:14 AM
P385: Predictors of tissue healing in ulcerative colitis patients treated with anti-TNF
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Viazis*1, M. Giakoumis1, G. Bamias2, D. Goukos2, T. Koukouratos1, J. Anastasiou1, K. Katopodi1, S. Ladas2, D. Karamanolis1

Created: Friday, 22 February 2019, 9:49 AM
P385: Results of a teleconsultation campaign for Inflammatory Bowel Disease (IBD) patients to check their treatment adherence and assess their level of anxiety during the first COVID-19 lockdown
Year: 2021
Source: ECCO'21 Virtual
Authors: Paupard, T.(1);richez, C.(2);verlynde, J.(1);zaharia, O.(1);quartier, G.(1);hudziak, H.(1);delhoustal, L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P385: Risk-benefit assessment of IBD drugs: a physicians and patients survey
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Amico, F.(1)*;Caron, B.(2);Vieujean, S.(3);Peyrin-Biroulet, L.(2);Danese, S.(1);
Created: Friday, 14 July 2023, 11:05 AM
P385: Tailoring induction treatment for children with Crohn’s disease.
Year: 2022
Source: ECCO'22
Authors: Cuomo, M.(1);Carobbio, A.(2);Aloi , M.(3);Alvisi , P.(4);Banzato, C.(5);Bosa, L.(6);Bramuzzo, M.(7);Campanozzi, A.(8);Catassi , G.(3);D'Antiga, L.(2);Di Paola, M.(9);Felici, E.(10);Fioretti , M.T.(11);Gatti , S.(12);Graziano, F.(13);Lega , S.(7);Lionetti , P.(9);Marseglia , A.(14);Martinelli , M.(11);Musto, F.(15);Sansotta, N.(2);Scarallo , L.(9);Zuin, G.(15);Norsa, L.(16);
Created: Friday, 11 February 2022, 3:52 PM
P385: TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Verstockt*1,2, S. Verstockt3, J. Dehairs4, V. Ballet1, H. Blevi2, W-J. Wollants2, C. Breynaert5, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

Created: Friday, 22 February 2019, 9:41 AM
P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M.J. Casanova1, M. Chaparro2, O. Nantes3, J.M. Benítez4, M. Rojas-Feria5, J. Castro-Poceiro6, J.M. Huguet7, A. Martín-Cardona8, M. Aicart9, J. Tosca10, M.D.M. Martín-Rodríguez11, C. González-Muñoza12, M. Mañosa13, E. Leo-Carnerero14, L. Lamuela15, I. Pérez-Martínez16, L. Bujanda17, J. Hinojosa18, R. Pajares19, F. Argüelles-Arias20, J.L. Pérez-Calle21, G.E. Rodríguez-González22, J. Guardiola23, M. Barreiro-de Acosta24, F. Bermejo25, J. Barrio26, B. Beltrán27, F. Gomollón28, R. Lorente29, A. Gutierrez30, M. Domínguez-Cajal31, C. Dueñas32, A. Ponferrada-Díaz33, M. Van Domselaar34, P. Ramírez-de la Piscina35, L. Ramos36, P. Almela37, M. Navarro-Llavat38, B. Botella39, J.P. Gisbert2, EVODIS

Created: Thursday, 30 January 2020, 10:12 AM
P386: A target 6-thioguanine nucleotide ≥125 is associated with a higher rate and longer durability of response in infliximab–thiopurine combination therapy: a retrospective study in Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Luber R.*1,2, Kariyawasam V.3, Dawson L.1, Munari S.1, Gibson P.1,2, Sparrow M.1,2, Ward M.1,2

Created: Wednesday, 20 February 2019, 10:36 AM
P386: Anti-TNF alpha as induction and maintenance therapy in ulcerative colitis patients in the BioColitis Registry in Germany
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. Bokemeyer*1, T. Krummenerl2, C. Maaser3, J. Büning4, R. Atreya5, A. Lügering6, U. Helwig7, P. Jessen8, P. Hartmann9, S. Schreiber10

Created: Friday, 22 February 2019, 9:49 AM